A randomized, open-label, phase 2 study of MDV3100 as a neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer

Trial Profile

A randomized, open-label, phase 2 study of MDV3100 as a neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Enzalutamide (Primary) ; Dutasteride; Leuprorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Medivation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov records.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top